Citadel Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36.8M | Sell |
47,687
-97,283
| -67% | -$74.5M | 0.01% | 1652 |
|
|
2025
Q4 | $112M | Sell |
144,970
-85,257
| -37% | -$57.9M | 0.02% | 784 |
|
|
2025
Q3 | $129M | Sell |
230,227
-450,278
| -66% | -$255M | 0.02% | 681 |
|
|
2025
Q2 | $357M | Buy |
680,505
+605,603
| +809% | +$338M | 0.06% | 227 |
|
|
2025
Q1 | $47.5M | Sell |
74,902
-117,444
| -61% | -$80.8M | 0.01% | 1195 |
|
|
2024
Q4 | $137M | Buy |
192,346
+122,086
| +174% | +$102M | 0.02% | 565 |
|
|
2024
Q3 | $73.9M | Sell |
70,260
-39,296
| -36% | -$43.7M | 0.01% | 923 |
|
|
2024
Q2 | $115M | Buy |
109,556
+30,978
| +39% | +$30M | 0.02% | 607 |
|
|
2024
Q1 | $75.6M | Sell |
78,578
-206,013
| -72% | -$196M | 0.01% | 905 |
|
|
2023
Q4 | $250M | Buy |
284,591
+220,135
| +342% | +$181M | 0.05% | 266 |
|
|
2023
Q3 | $53M | Buy |
64,456
+24,730
| +62% | +$19.4M | 0.01% | 1025 |
|
|
2023
Q2 | $28.5M | Sell |
39,726
-251,520
| -86% | -$194M | 0.01% | 1528 |
|
|
2023
Q1 | $239M | Buy |
291,246
+214,170
| +278% | +$162M | 0.05% | 253 |
|
|
2022
Q4 | $55.6M | Buy |
77,076
+58,926
| +325% | +$43.5M | 0.01% | 1043 |
|
|
2022
Q3 | $12.5M | Buy |
18,150
+8,956
| +97% | +$5.64M | ﹤0.01% | 2442 |
|
|
2022
Q2 | $5.43M | Sell |
9,194
-8,803
| -49% | -$5.72M | ﹤0.01% | 3642 |
|
|
2022
Q1 | $12.6M | Sell |
17,997
-81,923
| -82% | -$51.8M | ﹤0.01% | 2610 |
|
|
2021
Q4 | $63.1M | Sell |
99,920
-9,603
| -9% | -$5.9M | 0.01% | 985 |
|
|
2021
Q3 | $66.3M | Buy |
109,523
+51,755
| +90% | +$32.1M | 0.01% | 920 |
|
|
2021
Q2 | $32.3M | Buy |
57,768
+38,085
| +193% | +$19.3M | 0.01% | 1538 |
|
|
2021
Q1 | $9.31M | Sell |
19,683
-19,338
| -50% | -$9.42M | ﹤0.01% | 3077 |
|
|
2020
Q4 | $18.9M | Buy |
39,021
+23,016
| +144% | +$12.4M | ﹤0.01% | 1866 |
|
|
2020
Q3 | $8.96M | Buy |
+16,005
| New | +$9.7M | ﹤0.01% | 2417 |
|
|
2020
Q2 | – | Sell |
-23,514
| Closed | -$13.3M | – | 10380 |
|
|
2020
Q1 | $11.5M | Sell |
23,514
-372,365
| -94% | -$154M | 0.01% | 1714 |
|
|
2019
Q4 | $149M | Buy |
395,879
+240,518
| +155% | +$80.9M | 0.06% | 258 |
|
|
2019
Q3 | $43.1M | Sell |
155,361
-417,518
| -73% | -$124M | 0.02% | 847 |
|
|
2019
Q2 | $179M | Buy |
572,879
+394,489
| +221% | +$131M | 0.08% | 192 |
|
|
2019
Q1 | $73.3M | Buy |
178,390
+109,848
| +160% | +$45.2M | 0.04% | 507 |
|
|
2018
Q4 | $25.6M | Buy |
68,542
+25,509
| +59% | +$9.34M | 0.01% | 1042 |
|
|
2018
Q3 | $17.4M | Sell |
43,033
-12,943
| -23% | -$4.93M | 0.01% | 1527 |
|
|
2018
Q2 | $19.3M | Buy |
55,976
+26,745
| +91% | +$8.36M | 0.01% | 1346 |
|
|
2018
Q1 | $10.1M | Sell |
29,231
-155,855
| -84% | -$54.2M | 0.01% | 1721 |
|
|
2017
Q4 | $69.6M | Buy |
185,086
+177,431
| +2,318% | +$71.9M | 0.04% | 467 |
|
|
2017
Q3 | $3.42M | Sell |
7,655
-152,085
| -95% | -$72.4M | ﹤0.01% | 2741 |
|
|
2017
Q2 | $78.5M | Buy |
159,740
+53,698
| +51% | +$23.5M | 0.07% | 302 |
|
|
2017
Q1 | $41.1M | Sell |
106,042
-279,618
| -73% | -$104M | 0.04% | 542 |
|
|
2016
Q4 | $142M | Buy |
385,660
+257,659
| +201% | +$98M | 0.14% | 108 |
|
|
2016
Q3 | $51.5M | Sell |
128,001
-15,730
| -11% | -$6.31M | 0.05% | 371 |
|
|
2016
Q2 | $50.2M | Buy |
143,731
+123,620
| +615% | +$47.6M | 0.06% | 337 |
|
|
2016
Q1 | $7.25M | Buy |
20,111
+18,741
| +1,368% | +$7.72M | 0.01% | 1456 |
|
|
2015
Q4 | $744K | Sell |
1,370
-67,499
| -98% | -$36.6M | ﹤0.01% | 3958 |
|
|
2015
Q3 | $32M | Sell |
68,869
-292,083
| -81% | -$157M | 0.03% | 623 |
|
|
2015
Q2 | $184M | Buy |
360,952
+56,675
| +19% | +$27.7M | 0.16% | 113 |
|
|
2015
Q1 | $137M | Buy |
304,277
+285,521
| +1,522% | +$121M | 0.13% | 146 |
|
|
2014
Q4 | $7.7M | Sell |
18,756
-110,546
| -85% | -$43.5M | 0.01% | 1609 |
|
|
2014
Q3 | $46.6M | Buy |
129,302
+94,107
| +267% | +$31.5M | 0.05% | 451 |
|
|
2014
Q2 | $9.94M | Buy |
35,195
+24,371
| +225% | +$7.22M | 0.01% | 1275 |
|
|
2014
Q1 | $3.25M | Sell |
10,824
-167,842
| -94% | -$51.7M | ﹤0.01% | 2148 |
|
|
2013
Q4 | $49.2M | Sell |
178,666
-204,906
| -53% | -$58.9M | 0.06% | 363 |
|
|
2013
Q3 | $120M | Buy |
383,572
+359,420
| +1,488% | +$94.5M | 0.18% | 95 |
|
|
2013
Q2 | $5.43M | Buy |
+24,152
| New | +$5.62M | 0.01% | 1496 |
|
Other funds holding REGN
VCM
N
Citadel Advisors's REGN Position: Q1 2026 in Review
Citadel Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 67% in Q1 2026, selling an estimated $74.5M and leaving 47,687 shares worth $36.8M. The position accounts for 0.01% of the portfolio, ranked #1652.
Citadel Advisors first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $357M in Q2 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Citadel Advisors held 47,687 shares of Regeneron Pharmaceuticals worth $36.8M as of Q1 2026.
- Citadel Advisors sold 97,283 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $74.5M.
- Regeneron Pharmaceuticals made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1652 holding.
- Citadel Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Citadel Advisors's Regeneron Pharmaceuticals position peaked at $357M in Q2 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.